Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online February 1, 2023.
Article Versions
- You are currently viewing a Latest version of this article (February 1, 2023 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2023 The Journal of Rheumatology
Author Information
- Uta Kiltz,
- Désirée van der Heijde,
- Annelies Boonen,
- Lianne S. Gensler,
- Theresa Hunter Gibble,
- Jiaying Guo,
- Hilde Carlier and
- Juergen Braun
- U. Kiltz, MD, Rheumazentrum Ruhrgebiet, Herne, and Ruhr-Universität Bochum, Bochum, Germany.
- D. van der Heijde, MD, PhD, Leiden University Medical Center, Leiden, the Netherlands.
- A. Boonen, MD, PhD, Maastricht University Medical Center, and Caphri Research Institute, Maastricht University, Maastricht, the Netherlands.
- L.S. Gensler, MD, University of California, San Francisco, San Francisco, California, USA.
- T. Hunter Gibble, PhD, Eli Lilly and Company, Indianapolis, Indiana, USA.
- J. Guo, MS, Eli Lilly and Company, Indianapolis, Indiana, USA.
- H. Carlier, MD, Eli Lilly and Company, Indianapolis, Indiana, USA.
- B. Juergen, MD, Rheumazentrum Ruhrgebiet, Herne, and Ruhr-Universität Bochum, Bochum, Germany.
-
Funding for this study was provided by Eli Lilly and Company, which was involved in the study design, data collection, data analysis, and preparation of the manuscript.
UK received grant and research support and consultancy fees from AbbVie, Amgen, Biogen, Chugai, Eli Lilly and Company, Grünenthal, Hexal, Janssen, Merck Sharpe & Dohme, Novartis, Pfizer, Roche, and UCB. DvdH received consulting fees from AbbVie, Bayer, BMS, Cyxone, Eisai, Eli Lilly and Company, Galapagos, Gilead, Glaxo-Smith-Kline, Janssen, Novartis, Pfizer, and UCB Pharma. AB received department research grants from AbbVie and department compensations for lectures or consulting fees from Novartis, AbbVie, Galapagos, and Eli Lilly and Company. LSG received grants from Novartis and UCB and personal fees from AbbVie, Eli Lilly and Company, Galapagos, Janssen, Novartis, Pfizer, and UCB, outside the submitted work. TH, JG, and HC are current employees and shareholders of Eli Lilly and Company. JB received honoraria for talks and advisory boards, paid consultancies, and grants for studies from AbbVie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, Merck Sharpe & Dohme (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis, and UCB.
Address correspondence to Dr. T. Hunter Gibble, Lilly Corporate Center, 893 Delaware Street, Indianapolis, IN 46285, USA. Email: hunter_theresa_marie@lilly.com.
Accepted for publication December 4, 2022.